Heterocyclic Compounds, 4 or More Rings
"Heterocyclic Compounds, 4 or More Rings" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of heterocyclic compounds that include four or more fused rings. Both aromatic or non-aromatic ring structures are included in this category.
Descriptor ID |
D006576
|
MeSH Number(s) |
D03.633.400
|
Concept/Terms |
Heterocyclic Compounds, 4 or More Rings- Heterocyclic Compounds, 4 or More Rings
- Heterocyclic Compounds with 4 or More Rings
- Heterocyclic Cpds, 4 or More Rings
- Heterocyclic Compounds with Four or More Rings
Heterocyclic Compounds, 5-Ring- Heterocyclic Compounds, 5-Ring
- 5-Ring Heterocyclic Compounds
- Heterocyclic Compounds, 5 Ring
- Heterocyclic Cpds, 5 Ring
- Five Ring Heterocyclic Compounds
- Fused Heterocyclic Compounds, Five-Ring
- Fused Heterocyclic Compounds, Five Ring
Heterocyclic Compounds, 4-Ring- Heterocyclic Compounds, 4-Ring
- 4-Ring Heterocyclic Compounds
- Heterocyclic Compounds, 4 Ring
- Heterocyclic Cpds, 4 Ring
- Four Ring Heterocyclic Compounds
- Fused Heterocyclic Compounds, Four-Ring
- Fused Heterocyclic Compounds, Four Ring
|
Below are MeSH descriptors whose meaning is more general than "Heterocyclic Compounds, 4 or More Rings".
Below are MeSH descriptors whose meaning is more specific than "Heterocyclic Compounds, 4 or More Rings".
This graph shows the total number of publications written about "Heterocyclic Compounds, 4 or More Rings" by people in this website by year, and whether "Heterocyclic Compounds, 4 or More Rings" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2004 | 1 | 0 | 1 |
2005 | 1 | 0 | 1 |
2006 | 3 | 0 | 3 |
2008 | 0 | 1 | 1 |
2011 | 1 | 0 | 1 |
2012 | 1 | 1 | 2 |
2013 | 2 | 0 | 2 |
2014 | 0 | 1 | 1 |
2015 | 0 | 2 | 2 |
2016 | 3 | 2 | 5 |
2017 | 4 | 1 | 5 |
2018 | 5 | 2 | 7 |
2019 | 5 | 3 | 8 |
2020 | 3 | 2 | 5 |
2021 | 3 | 0 | 3 |
2022 | 1 | 2 | 3 |
2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Heterocyclic Compounds, 4 or More Rings" by people in Profiles.
-
Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval =30 days and without central nervous metastases. Lung Cancer. 2024 02; 188:107448.
-
Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study. Eur J Cancer. 2022 09; 172:340-348.
-
Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial. JAMA Oncol. 2022 07 01; 8(7):1047-1052.
-
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study. Clin Cancer Res. 2022 07 01; 28(13):2762-2770.
-
Integrated safety analysis of umbralisib, a dual PI3Kd/CK1e inhibitor, in relapsed/refractory lymphoid malignancies. Blood Adv. 2021 12 14; 5(23):5332-5343.
-
Synthesis and structure activity relationship of the first class of LXR inverse agonists. Bioorg Chem. 2022 02; 119:105540.
-
The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action. Blood Cancer J. 2021 03 13; 11(3):57.
-
Umbralisib, a Dual PI3Kd/CK1e Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. J Clin Oncol. 2021 05 20; 39(15):1609-1618.
-
Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis. Cancer Chemother Pharmacol. 2021 01; 87(1):113-124.
-
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. Lung Cancer. 2020 12; 150:90-96.